Abstract: A plurality of photovoltaic (PV) modules are configured into a PV string to generate a PV string voltage in a solar power system. The number of PV modules per PV string is based on operating conditions at the solar power system site and cause the PV string voltage to exceed a maximum voltage specification when operating at the lowest expected ambient temperature at the site, but only exceeds the maximum voltage specification for a limited number of occurrences for which the operating conditions at the site cause the PV string voltage to exceed the maximum voltage specification. Under control of a string voltage control circuit, voltage bypass circuits selectively bypass the bypass photovoltaic module so as to eliminate the PV module from the PV string voltage when the operating conditions at the site cause the PV string voltage to exceed the maximum voltage specification.

Abstract: Provided are a locking device, a photovoltaic module mounting structure and a photovoltaic system. The locking device includes a blocking portion, a plug portion, and a guide portion. The blocking portion protrudes from the guide rail and is provided with a clamping groove for clamping a frame of the solar module. The plug portion is connected to the blocking portion, and the plug portion is configured to be in plug-in fit with the guide rail. The guide portion is connected to the blocking portion and provided with a guide ramp, one end of the guide ramp is flush with a notch of the clamping groove, and the other end of the guide ramp extends obliquely downward along a length direction of the guide rail.

Abstract: A plurality of photovoltaic (PV) modules are configured into a PV string to generate a PV string voltage in a solar power system. The number of PV modules per PV string is based on operating conditions at the solar power system site and cause the PV string voltage to exceed a maximum voltage specification when operating at the lowest expected ambient temperature at the site, but only exceeds the maximum voltage specification for a limited number of occurrences for which the operating conditions at the site cause the PV string voltage to exceed the maximum voltage specification. Under control of a string voltage control circuit, voltage bypass circuits selectively bypass the bypass photovoltaic module so as to eliminate the PV module from the PV string voltage when the operating conditions at the site cause the PV string voltage to exceed the maximum voltage specification.

Abstract: This disclosure generally relates to solar module mounting and racking. More specifically, this disclosure relates to integrated solar racking systems, which facilitate slide and snap in place mounting technology that achieves solar module mounting and electrical grounding. This design eliminates the need for mounting fasteners and tools, and facilitates reliable and repeatable installation.

Abstract: Provided are a locking device, a photovoltaic module mounting structure and a photovoltaic system. The locking device includes a blocking portion, a plug portion, and a guide portion. The blocking portion protrudes from the guide rail and is provided with a clamping groove for clamping a frame of the solar module. The plug portion is connected to the blocking portion, and the plug portion is configured to be in plug-in fit with the guide rail. The guide portion is connected to the blocking portion and provided with a guide ramp, one end of the guide ramp is flush with a notch of the clamping groove, and the other end of the guide ramp extends obliquely downward along a length direction of the guide rail.

Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.

Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

Abstract: A method for actuating a controlled device in response to a pre-crash condition of a vehicle, wherein the vehicle includes at least two sensors each of which is capable of generating a signal, wherein the method includes the steps of monitoring the signals, determining a panic index based upon the signals and, when the determined panic index exceeds a predetermined threshold value, actuating the controlled device.

Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.

Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage ?FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.

Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.

Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.

Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.

Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.

Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.

Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.

Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteaces are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.

Abstract: A haptic braking method and system is disclosed. A controller operates a pump to apply brake fluid to a brake when it is necessary to decelerate a wheel during an active cruise control mode of a vehicle. The controller further operates one or more valves to cyclically vary a pressure level of the brake fluid to cause one or more haptic movements of the brake.